Boston Scientific (BSX)

PART I FINANCIAL INFORMATION ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Three Months Ended June 30,Six Months Ended June 30, (in millions, except per share data)2026202520262025 Net sales$5,442 $5,061 $10,646 $9,724 Cost of products sold (excluding amortization expense)1,594 1,637 3,184 3,090 Gross profit3,848 3,424 7,462 6,633 Operating expenses: Selling, general and administrative expenses1,803 1,716 3,583 3,312 Research and development expenses554 526 1,069 969 Royalty expense12 14 24 28 Amortization expense233 225 466 444 46 46 Contingent consideration net expense (benefit)(16)(5)(46)0 Restructuring net charges (credits)8 83 11 93 Litigation-related net charges (credits)76 76 2,605 5,183 4,894 Operating income (loss)1,178 819 2,279 1,740 Other income (expense): Interest expense(96)(90)(186)(172) Other, net(23)213 129 179 Income (loss) before income taxes1,060 941 2,222 1,746 Income tax expense (benefit)155 146 (21)279 Net income (loss)905 795 2,243 1,467 (2)(2)(4)(4) Net income (loss) attributable to Boston Scientific common stockholders$907 $797 $2,247 $1,471 Net income (loss) per common share basic$0.62 $0.54 $1.52 $0.99 Net income (loss) per common share diluted$0.61 $0.53 $1.51 $0.98 Weighted-average shares outstanding Basic1,470.2 1,479.9 1,477.6 1,478.5 Diluted1,474.8 1,493.5 1,484.9 1,493.3 Refer to notes to the unaudited consolidated financial statements. Amounts may not add due to rounding. 4 Table of Contents BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) Three Months Ended June 30,Six Months Ended June 30, (in millions)2026202520262025 Net income (loss)$905 $795 $2,243 $1,467 Other comprehensive income (loss), net of tax: Foreign currency translation adjustment84 (477)218 (691) Net change in derivative financial instruments15 (214)93 (300) (0)(0)0 (0) Other comprehensive income (loss)98 (691)312 (991) Comprehensive income (loss)$1,002 $104 $2,555 $476 Net income (loss) attributable to noncontrolling interests(2)(2)(4)(4) Other comprehensive income (loss) attributable to noncontrolling interests4 3 7 6 Comprehensive income (loss) attributable to noncontrolling interests2 1 3 2 Comprehensive income (loss) attributable to Boston Scientific common stockholders$1,000 $103 $2,552 $474 Refer to notes to the unaudited consolidated financial statements. Amounts may not add due to rounding. 5 Table of Contents BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (UNAUDITED) As of (in millions, except share and per share data)June 30, 2026December 31, 2025 ASSETS Current assets: Cash and cash equivalents$539 $1,965 Trade accounts receivable, net3,049 2,926 Inventories3,235 2,943 Prepaid income taxes390 299 760 660 Total current assets7,972 8,794 Other investments2,245 681 Property, plant and equipment, net4,126 4,036 Goodwill18,640 18,282 Other intangible assets, net6,918 7,019 Deferred tax assets3,909 3,675 Other long-term assets1,405 1,185 TOTAL ASSETS$45,216 $43,673 LIABILITIES AND STOCKHOLDERS EQUITY Current liabilities: Current debt obligations$1,709 $299 Accounts payable1,231 1,144 Accrued expenses2,756 3,201 Other current liabilities732 795 Total current liabilities6,428 5,439 Long-term debt10,915 11,137 Deferred tax liabilities221 220 Other long-term liabilities2,480 2,405 Commitments and contingencies Stockholders equity Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of June 30, 2026 and December 31, 2025 Common stock, $0.01 par value - authorized 2,000,000,000 shares - 1,749,917,975 shares issued as of June 30, 2026 and 1,746,290,165 shares issued as of December 31, 2025 17 17 Treasury stock, at cost - 303,212,284 shares as of June 30, 2026 and 263,289,848 shares as of December 31, 2025 (4,318)(2,251) Additional paid-in capital21,717 21,505 Retained earnings7,818 5,571 Accumulated other comprehensive income (loss), net of tax(304)(610) Total stockholders equity24,930 24,233 Noncontrolling interests242 239 Total equity25,172 24,472 TOTAL LIABILITIES AND EQUITY$45,216 $43,673 Refer to notes to the unaudited consolidated financial statements. Amounts may not add due to rounding. 6 Table of Contents BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) Three Months Ended June 30,Six Months Ended June 30, (in millions, except share data)2026202520262025 Beginning1,749,584,1511,742,488,3281,746,290,1651,737,846,196 333,824 1,144,543 3,627,810 5,786,675 1,749,917,975 1,743,632,871 1,749,917,975 1,743,632,871 Beginning$17 $17 $17 $17 0 0 0 0 $17 $17 $17 $17 Treasury stock Beginning$(2,251)$(2,251)$(2,251)$(2,251) Repurchase of common stock(1) (2,067) (2,067) Ending$(4,318)$(2,251)$(4,318)$(2,251) Additional paid-in capital Beginning$21,584 $21,127 $21,505 $21,056 48 48 85 103 164 174 Ending$21,717 $21,230 $21,717 $21,230 Retained earnings Beginning$6,912 $3,347 $5,571 $2,673 Net income (loss)905 795 2,243 1,467 Net (income) loss attributable to noncontrolling interests2 2 4 4 $7,818 $4,144 $7,818 $4,144 Accumulated other comprehensive income (loss), net of tax Beginning$(398)$(28)$(610)$275 Changes in other comprehensive income (loss)94 (694)305 (996) Ending$(304)$(722)$(304)$(722) Total stockholders' equity$24,930 $22,418 $24,930 $22,418 Noncontrolling interests Beginning$240 $233 $239 $233 Net income (loss) attributable to noncontrolling interests(2)(2)(4)(4) Changes in other comprehensive income (loss)4 3 7 6 $242 $235 $242 $235 Total equity$25,172 $22,653 $25,172 $22,653 (1) Amounts recorded to Treasury stock include excise tax on share repurchases. Refer to notes to the unaudited consolidated financial statements. Amounts may not add due to rounding. 7 Table of Contents BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Six Months Ended June 30, (in millions)20262025 Net income (loss)$2,243 $1,467 Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities 706 661 Deferred and prepaid income taxes(334)(49) Stock-based compensation expense170 149 Goodwill and other intangible asset impairment charges 46 Net loss (gain) on investments and notes receivable(146)(191) Contingent consideration net expense (benefit)(46)0 Inventory step-up amortization6 118 63 72 Increase (decrease) in operating assets and liabilities, excluding purchase accounting: Trade accounts receivable(163)(139) Inventories(310)(44) Other assets(90)(108) Accounts payable, accrued expenses and other liabilities(278)(154) Cash provided by (used for) operating activities1,822 1,827 Investing activities: Purchases of property, plant and equipment and internal use software(372)(344) (718)(1,248) Proceeds from sale of investments and dispositions of certain technologies229 55 Payments for investments and acquisitions of certain technologies(1,730)(165) 43 76 Cash provided by (used for) investing activities(2,547)(1,626) Financing activities: Payment of contingent consideration previously established in purchase accounting(78)(62) (0)(42) Payments on short-term borrowings(272)(1,583) 1,675 1 1,558 (88)(123) Repurchase of common stock(2,000) Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans86 147 Other, net8 (3) Cash provided by (used for) financing activities(670)(107) Effect of foreign exchange rates on cash1 41 Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents(1,394)135 Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period2,147 606 Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$753 $741 Refer to notes to the unaudited consolidated financial statements. Amounts may not add due to rounding. 8 Table of Contents BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (SUPPLEMENTAL INFORMATION) As of June 30, (in millions)20262025 Reconciliation to amounts within the unaudited consolidated balance sheets: Cash and cash equivalents$539 $534 Restricted cash and restricted cash equivalents included in Other current assets 81 109 Restricted cash equivalents included in Other long-term assets 133 98 Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$753 $741 Refer to notes to the unaudited consolidated financial statements. Amounts may not add due to rounding. 9 Table of Contents NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) NOTE A BASIS OF PRESENTATION The accompanying unaudited consolidated financial statements of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X, and they do not include all of the information and footnotes required by GAAP for complete financial statements. When used in this report, the terms, "we," "us," "our," and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three and six months ended June 30, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026. Accordingly, our unaudited consolidated financial statements and footnotes thereto should be read in conjunction with our audited consolidated financial statements and footnotes thereto included in Item 8 of our most recent Annual Report on Form 10-K. The accompanying unaudited consolidated financial statements include the accounts of the Company's wholly owned- subsidiaries and entities for which we have a controlling financial interest. All intercompany balances and transactions have been eliminated in consolidation. We consolidate our majority stake investment in Acotec Scientific Holdings Limited on a one quarter lag. Amounts reported in millions within this Quarterly Report on Form 10-Q are computed based on the amounts in thousands. As a result, the sum of the components may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts. Subsequent Events We evaluate events occurring after the date of our accompanying unaudited consolidated balance sheets for potential recognition or disclosure in our unaudited consolidated financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note H Commitments and Contingencies and Note M - Restructuring-Related Activities for further details. NOTE B ACQUISITIONS AND STRATEGIC INVESTMENTS Our accompanying unaudited consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our accompanying unaudited consolidated financial statements. Further, transaction costs were immaterial to our accompanying unaudited consolidated financial statements and were expensed as incurred. On March 31, 2026, we entered into a definitive agreement to acquire 100 percent of Scivita Medical Technology Co., Ltd. (Scivita Medical), a privately held medical technology company focused on the development and commercialization of innovative medical endoscopes and related products. We have been an investor in Scivita Medical since 2024 and currently own an equity stake of approximately one percent. The transaction price to acquire the remaining stake is expected to result in an upfront cash payment of $200 million in addition to cash acquired upon closing and up to an additional $30 million in future payments upon achievement of commercialization milestones. The transaction is expected to close during the third quarter of 2026, subject to customary closing conditions. The Scivita Medical portfolio complements our existing Endoscopy and Urology portfolios which will provide physicians with more treatment options to meet specific patient needs. On January 15, 2026, we announced our entry into a definitive agreement to acquire 100 percent of Penumbra, Inc. (Penumbra), a publicly traded medical technology company primarily focused on thrombectomy products for use in peripheral vascular procedures in the removal of blood clots and blockages. At the time of announcement, the purchase price was valued at $374 per share, or approximately $14.500 billion. On March 16, 2026, we and Penumbra each received a request for additional information (Second Request) from the United States Federal Trade Commission (FTC) in connection with its review of the transaction. We and Penumbra are responding to the Second Request and continue to work cooperatively with the FTC in its review. On May 6, 2026, Penumbra stockholders voted to approve the acquisition. The transaction is expected to be completed 10 Table of Contents in the second half of 2026, subject to the satisfaction of other customary closing conditions, including regulatory clearances. The Penumbra business will be integrated into our Cardiovascular division. 2026 Acquisitions On January 27, 2026, we completed our acquisition of 100 percent of Nalu Medical, Inc. (Nalu Medical), a privately held medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic pain. We had been an investor in Nalu Medical since 2017 and previously held an equity stake of approximately nine percent. The transaction to acquire the remaining stake consisted of an upfront cash payment of approximately $523 million, net of cash acquired. The Nalu Medical business is being integrated into our Neuromodulation division. Purchase Price Allocation We accounted for this transaction as a business combination in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, Business Combinations (FASB ASC Topic 805). The preliminary purchase price was comprised of the amounts presented below: Nalu Medical$523 66 588 Nalu Medical$274 262 55 13 (16)588 Weighted Average Amortization Period (in years) Nalu Medical: Amortizable intangible assets: Technology-related$250 12 Customer relationships 12 12 262 11 Table of Contents Our intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives. In addition to the above, during the first six months of 2026, we completed acquisitions of other businesses for which the aggregate transaction price consisted of upfront cash payments of $195 million, net of cash acquired. 2025 Acquisitions On May 7, 2025, we completed our acquisition of the remaining shares of SoniVie Ltd. (SoniVie), a privately held medical device company that has developed the TIVUS Intravascular Ultrasound System. An investigational technology, the TIVUS system is designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation for hypertension. We had been an investor in SoniVie since 2022 and held an equity stake of approximately 10 percent immediately prior to the acquisition date. The transaction price to acquire the remaining stake consisted of an upfront cash payment of $362 million, net of cash acquired after adjustments for our prior equity stake and other closing adjustments, and an additional future payment of up to $200 million, or $180 million for the portion not previously owned, upon achievement of a regulatory milestone. The SoniVie business is being integrated into our Cardiovascular division. On April 1, 2025, we completed our acquisition of the remaining shares of Bolt Medical, Inc. (Bolt Medical), the developer of an intravascular lithotripsy advanced laser-based platform for the treatment of coronary and peripheral artery disease. We had been an investor in Bolt Medical since 2019 and held an equity stake of approximately 26 percent immediately prior to the acquisition date. The transaction price to acquire the remaining stake consisted of an upfront cash payment of $475 million, net of cash acquired after adjustments for our prior equity stake, debt and other closing adjustments, including Bolt Medical's achievement of a regulatory milestone. In addition, the transaction price consists of a future payment of up to $200 million, or approximately $148 million for the portion not previously owned, upon achievement of a second regulatory milestone. The Bolt Medical business is being integrated into our Cardiovascular division. On January 24, 2025, we completed our acquisition of 100 percent of Cortex, Inc. (Cortex), a privately held medical technology company focused on the development of a diagnostic mapping solution which may identify triggers and drivers outside of the pulmonary veins that are foundational to atrial fibrillation (AF). The transaction price consisted of an upfront cash payment of $239 million, net of cash acquired, and up to an additional $50 million in future payments upon achievement of clinical and other milestones. The Cortex business is being integrated into our Cardiovascular division. Purchase Price Allocation We accounted for these transactions as business combinations in accordance with FASB ASC Topic 805. The final purchase prices were comprised of the amounts presented below: (in millions)Bolt MedicalSoniVieOther Payment for acquisition, net of cash acquired$475 $362 $239 Fair value of contingent consideration100 98 38 Fair value of prior interest207 55 $782 $516 $277 12 Table of Contents We recorded the assets acquired and liabilities assumed at their respective fair values as of the closing date of the transactions. The final purchase price allocations were comprised of the components presented below, with the excess of the purchase price over the fair value of net assets acquired recorded to goodwill: (in millions)Bolt MedicalSoniVieOther Goodwill$304 $248 $208 Amortizable intangible assets142 66 Indefinite-lived intangible assets376 344 Other assets acquired28 12 1 Net deferred tax assets 12 Liabilities assumed(22)(23)(10) Net deferred tax liabilities(46)(65) $782 $516 $277 Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies, none of which is deductible for tax purposes. We allocated a portion of the purchase prices to the specific intangible asset categories as follows: Amount Assigned (in millions) Weighted Average Amortization Period (in years) Bolt Medical: Amortizable intangible assets: Technology-related$142 12 In-process research and development (IPR&D)$376 N/A $518 SoniVie: IPR&D$344 N/A $344 Other: Amortizable intangible assets: Technology-related$66 13 66 Our intangible assets, including technology-related intangible assets and IPR&D, consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related and IPR&D intangible assets. Our amortizable intangibles are amortized on a straight-line basis over their assigned estimated useful lives. In addition to the above, during the first six months of 2025, we completed acquisitions of other businesses for which the aggregate transaction price consisted of upfront cash payments of $172 million, net of cash acquired. 13 Table of Contents Contingent Consideration Changes in the fair value of our contingent consideration liability during the first six months of 2026 associated with current and prior period acquisitions were as follows: (in millions) Balance as of December 31, 2025$385 (46) Contingent consideration payments(82) Balance as of June 30, 2026$257 The maximum amount for certain contingent consideration is not determinable as it is uncapped and based on a percent of certain sales. As of June 30, 2026, the fair value of such uncapped contingent consideration is estimated at $58 million. As of June 30, 2026, the maximum amount that we could be required to pay under our other capped contingent consideration arrangements (undiscounted) is approximately $596 million. Refer to Note B Acquisitions and Strategic Investments to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for additional information. The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs: Fair Value as of June 30, 2026Valuation TechniqueUnobservable InputRangeWeighted Average(1) $76 millionDiscounted Cash FlowDiscount Rate6%-15%10%90%-100%98%2027-20322029$181 millionDiscounted Cash FlowDiscount Rate4%-5%5%74%-86%81%2027-20292028As of (in millions)June 30, 2026December 31, 2025 Equity method investments$1,308 $396 Measurement alternative investments(1, 2) 938 286 $2,245 $681 (1) Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying unaudited consolidated statements of operations. (2) Includes publicly-held equity securities, convertible notes and securities measured at fair value with changes in fair value recognized in Other, net within our accompanying unaudited consolidated statements of operations. 14 Table of Contents On May 15, 2026, we entered into an investment agreement with MiRus LLC (MiRus), a privately held company developing and commercializing proprietary novel biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases, including the SIEGEL Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system (TAVR System), for which it has received investigation device exemption approval from the U.S. Federal Food and Drug Administration (FDA) to conduct the STAR (Siegel Transcatheter Aortic Valve Replacement Trial) randomized control clinical trial in the United States designed to achieve Premarket Approval for the TAVR System. Under the terms of the agreement, for a cash payment of $1.500 billion, exclusive of a $100 million payment previously made by the Company to MiRus, we acquired (a) non-voting common equity interests constituting approximately 33.75 percent of the fully diluted equity interests of MiRus, and (b) an exclusive option (the TAVR Option) to acquire the MiRus TAVR business (TAVR-Structural Heart NewCo), for additional aggregate cash payments totaling $3.000 billion, at our option following MiRus achievement of certain clinical and regulatory milestones, for 100 percent ownership of TAVR-Structural Heart NewCo. Upon the closing of our acquisition of TAVR-Structural Heart NewCo, we will no longer own any equity interest in MiRus. If we exercise the TAVR Option, MiRus will have the right to receive additional payments based on net sales of the TAVR System over a specified period. We also have an exclusive option, exercisable if we exercise the TAVR Option, to acquire mitral and tricuspid replacement valve assets from MiRus for an additional payment. If we do not make any portion of the additional payments, or do not exercise the TAVR Option within the applicable period or the TAVR Option does not close following its exercise, our equity interest in MiRus will be forfeited or reduced by approximately 75 percent, or exchanged for an interest in TAVR-Structural Heart NewCo, depending on the circumstances. The $1.600 billion paid to MiRus was allocated based on the relative fair value of each component of the arrangement, including the equity investment in MiRus and the TAVR Option, each of which are classified as Other investments within our accompanying unaudited consolidated balance sheets. As the agreement provides us with the ability to exert significant influence over MiRus, our equity investment in MiRus is accounted for under the equity method of accounting in accordance with FASB ASC Topic 323, Investments - Equity Method and Joint Ventures. The investment in the TAVR Option is recorded at the initial allocated cost and will be assessed for impairment on a quarterly basis. As of June 30, 2026, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $1.311 billion, which represents amortizable intangible assets, IPR&D, goodwill and deferred tax liabilities. NOTE C GOODWILL AND OTHER INTANGIBLE ASSETS The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows: As of June 30, 2026As of December 31, 2025 (in millions)Gross Carrying AmountAccumulated Amortization/ Write-offsGross Carrying AmountAccumulated Amortization/ Write-offs Technology-related$15,065 $(9,755)$14,692 $(9,346) Patents502 (390)493 (382) Other intangible assets2,527 (1,801)2,482 (1,732) Amortizable intangible assets$18,094 $(11,946)$17,667 $(11,461) Goodwill$28,540 $(9,900)$28,182 $(9,900) IPR&D$770 $813 $770 $813 The increase in our balance of goodwill and intangible assets is related primarily to our recent acquisitions. Refer to Note B Acquisitions and Strategic Investments for further detail. 15 Table of Contents The following represents a roll forward of our goodwill balance by reportable segment: MedSurgCardiovascular Balance as of December 31, 2025$7,709 $10,574 18,282 378 Impact of foreign currency fluctuations and purchase price adjustments(4)(16) Balance as of June 30, 2026$8,082 $10,558 18,640 Goodwill and Other Intangible Asset Impairments We did not record any goodwill impairment charges in the first six months of 2026 or 2025. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist. We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. During the first quarter of 2026, an organizational change impacted the composition of reporting units within our Cardiovascular operating segment. Goodwill was reassigned to the affected reporting units based on their relative fair values and an interim goodwill impairment test as of the date of the reorganization was performed. The fair value of each affected reporting unit exceeded its carrying amount indicating no impairment. This change had no impact on our operating segments or reportable segments. In the second quarter of 2026, we performed our annual goodwill impairment test utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350, Intangibles - Goodwill and Other. The qualitative approach was used for testing certain reporting units where fair value has historically exceeded carrying value, and all other reporting units were tested using the quantitative approach. For the reporting units tested using the qualitative approach, after assessing the totality of events, it was determined that it was not more likely than not that the fair value of the reporting units was less than their carrying value, and it was not deemed necessary to proceed to the quantitative test. For the reporting units tested using the quantitative approach, we determined that the fair value of the reporting units exceeded the carrying value and concluded that goodwill was not impaired. We did not record any Intangible asset impairment charges in the second quarter and first six months of 2026 and recorded $46 million in the second quarter and first six months of 2025. We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified. We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. Refer to Note A Significant Accounting Policies to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for further discussion of our annual goodwill and intangible asset impairment testing. 16 Table of Contents NOTE D HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS Derivative Instruments and Hedging Activities Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities; forecasted intercompany and third-party transactions; and net investments in certain subsidiaries. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates. The success of our currency risk management program depends, in part, on forecasted transactions denominated primarily in euro, Chinese renminbi, Japanese yen, British pound sterling, Korean won, Australian dollar and Swiss franc. Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in euro, Chinese renminbi, Canadian dollar and Japanese yen. We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in euro. As of June 30, 2026 and December 31, 2025, we designated as a net investment hedge our 900 million in aggregate principal amount of 0.625% senior notes issued in November 2019 and due in 2027 (December 2027 Notes). We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecasted transactions. Refer to Note A Significant Accounting Policies to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for further discussion relating to derivative instruments and hedging activities. The following table presents the contractual amounts of our hedging instruments outstanding: (in millions)FASB ASC Topic 815 DesignationAs of June 30, 2026December 31, 2025 Forward currency contractsCash flow hedge$8,662 $7,270 Forward currency contractsNet investment hedge1,492 1,292 Foreign currency-denominated debt(1) Net investment hedge997 997 Forward currency contractsNon-designated4,231 4,163 $15,382 $13,723 (1) Foreign currency-denominated debt is the 900 million debt principal associated with our December 2027 Notes designated as a net investment hedge. The remaining time to maturity as of June 30, 2026 is within 60 months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature between one and two years. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027. The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 within our accompanying unaudited consolidated statements of operations. Refer to Note L Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within our accompanying unaudited consolidated statements of comprehensive income (loss). 17 Table of Contents Effect of Hedging Relationships on Accumulated Other Comprehensive Income Amount Recognized in OCI on HedgesUnaudited Consolidated Statements of Operations(1) Amount Reclassified from AOCI into Earnings (in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified Pre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax Three Months Ended June 30, 2026 Forward currency contracts Cash flow hedges$15 $(3)$12 Cost of products sold$4 $(1)$3 Net investment hedges(2) 19 (4)14 Interest expense(8)2 (6) Foreign currency-denominated debt Net investment hedges(3) 11 (2)8 Other, net Amount Recognized in OCI on HedgesUnaudited Consolidated Statements of Operations(1) Amount Reclassified from AOCI into Earnings (in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified Pre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax Three Months Ended June 30, 2025 Forward currency contracts Cash flow hedges$(255)$57 $(198)Cost of products sold$(21)$5 $(16) Net investment hedges(2) (61)14 (47)Interest expense(9)2 (7) Foreign currency-denominated debt Net investment hedges(3) (81)18 (63)Other, net Amount Recognized in OCI on HedgesUnaudited Consolidated Statements of Operations(1) Amount Reclassified from AOCI into Earnings (in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount ReclassifiedPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax Six Months Ended June 30, 2026 Forward currency contracts Cash flow hedges$114 $(26)$88 Cost of products sold$7 $(2)$5 Net investment hedges(2) 36 (8)28 Interest expense(11)2 (8) Foreign currency-denominated debt Net investment hedges(3) 32 (7)25 Other, net Amount Recognized in OCI on HedgesUnaudited Consolidated Statements of Operations(1) Amount Reclassified from AOCI into Earnings (in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount ReclassifiedPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax Six Months Ended June 30, 2025 Forward currency contracts Cash flow hedges$(325)$73 $(252)Cost of products sold$(61)$14 $(48) Net investment hedges(2) (78)18 (60)Interest expense(14)3 (11) Foreign currency-denominated debt Net investment hedges(3) (119)27 (93)Other, net Location on Unaudited Consolidated Statements of OperationsAmount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings Designated Hedging Instrument Forward currency contractsCash flow hedgeCost of products sold$21 Forward currency contractsNet investment hedgeInterest expense23 Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below: Location on Unaudited Consolidated Statements of OperationsThree Months Ended June 30,Six Months Ended June 30, (in millions)2026202520262025 Net gain (loss) on currency hedge contractsOther, net$5 $(132)$15 $(174) Net gain (loss) on currency transaction exposuresOther, net(20)131 (41)173 Net currency exchange gain (loss)$(15)$(0)$(26)$(1) Fair Value Measurements Refer to Note D Hedging Activities and Fair Value Measurements to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for discussion relating to our derivative and nonderivative instruments and fair value measurements. 19 Table of Contents The following are the balances of our derivative and nonderivative assets and liabilities: Location on Unaudited Consolidated Balance Sheets(1) As of (in millions)June 30, 2026December 31, 2025 Derivative and Nonderivative Assets: Designated Hedging Instruments Forward currency contractsOther current assets$100 $99 Forward currency contractsOther long-term assets110 57 209 156 Non-Designated Hedging Instruments Forward currency contractsOther current assets46 25 $255 $181 Derivative and Nonderivative Liabilities: Designated Hedging Instruments Forward currency contractsOther current liabilities$62 $109 Forward currency contractsOther long-term liabilities74 102 Foreign currency-denominated debt(2) Long-term debt1,023 1,055 1,266 Non-Designated Hedging Instruments Forward currency contractsOther current liabilities39 42 Total Derivative and Nonderivative Liabilities$1,198 $1,308 (1) We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less. (2) Foreign currency-denominated debt is the 900 million debt principal associated with our December 2027 Notes designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item. Recurring Fair Value Measurements Assets and liabilities measured at fair value on a recurring basis consist of the following: As of June 30, 2026December 31, 2025 (in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total Assets Money market funds and time deposits$210 $ $ $210 $1,075 $ $ $1,075 Publicly-held equity securities10 10 17 17 Hedging instruments 255 255 181 181 220 $255 $ $475 $1,092 $181 $ $1,273 Liabilities Hedging instruments$ $1,198 $ $1,198 $ $1,308 $ $1,308 Contingent consideration liability 257 257 385 385 Licensing arrangements 7 7 $ $1,198 $257 $1,455 $ $1,308 $392 $1,700 Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents or Other current assets within our accompanying unaudited consolidated balance sheets, in accordance with GAAP and our accounting policies. In addition to $210 million invested in money market funds and time deposits as of June 30, 2026 and $1.075 billion as of December 31, 2025, we held $409 million in interest-bearing and non-interest-bearing bank accounts as of June 30, 2026 and $965 million as of December 31, 2025. 20 Table of Contents Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to Note B Acquisitions and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability. Non-Recurring Fair Value Measurements We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B Acquisitions and Strategic Investments for a discussion of our strategic investments and Note C Goodwill and Other Intangible Assets for a discussion of the fair values of our intangible assets including goodwill. The fair value of our outstanding debt obligations, excluding finance leases, was $12.272 billion as of June 30, 2026 and $11.154 billion as of December 31, 2025. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to Note E Contractual Obligations and Commitments for a discussion of our debt obligations. NOTE E CONTRACTUAL OBLIGATIONS AND COMMITMENTS Borrowings and Credit Arrangements The debt maturity schedule for our long-term debt obligations is presented below: (in millions, except coupon rates)Issuance DateMaturity DateAs ofCoupon Rate(1) June 30, 2026December 31, 2025 November 2019December 20271,026 1,058 0.625% March 2028 Senior Notes(2) March 2022March 2028855 881 1.375% March 2028 Senior NotesFebruary 2018March 2028344 344 4.000% March 2029 Senior NotesFebruary 2019March 2029272 272 4.000% March 2029 Senior Notes(2) February 2024March 2029855 881 3.375% June 2030 Senior NotesMay 2020June 20301,200 1,200 2.650% March 2031 Senior Notes(2) March 2022March 2031855 881 1.625% March 2031 Senior Notes(2) February 2025March 2031969 999 3.000% March 2032 Senior Notes(2) February 2024March 20321,424 1,469 3.500% March 2034 Senior Notes(2) March 2022March 2034570 588 1.875% March 2034 Senior Notes(2) February 2025March 2034741 764 3.250% November 2035 Senior NotesNovember 2005November 2035350 350 6.250% March 2039 Senior NotesFebruary 2019March 2039450 450 4.550% January 2040 Senior NotesDecember 2009January 2040300 300 7.375% March 2049 Senior NotesFebruary 2019March 2049650 650 4.700% Unamortized Debt Issuance Discount and Deferred Financing Costs2026 - 2049(68)(76) Finance Lease ObligationVarious124 125 Long-term debt$10,915 $11,137 (1) Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon. (2) These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of June 30, 2026 and December 31, 2025, respectively. 21 Table of Contents Revolving Credit Agreement On February 26, 2026, we entered into a new $3.000 billion revolving credit agreement (the 2026 Revolving Credit Agreement) with a global syndicate of commercial banks and we terminated our previous revolving credit agreement (the 2021 Revolving Credit Agreement). The 2026 Revolving Credit Agreement matures on February 26, 2031, with one-year extension options subject to certain conditions, including certain lender approvals. Loans under the 2026 Revolving Credit Agreement will bear interest at applicable base rates plus an applicable margin based on our credit ratings. In addition, we will pay a facility fee based on our credit rating and the total amount of revolving credit commitments (generally irrespective of usage). The 2026 Revolving Credit Agreement contains customary representations, warranties, and covenants, including financial covenants as discussed below under Financial Covenant, as well as customary events of default, which may result in the termination of commitments and acceleration of any outstanding loans. The 2026 Revolving Credit Agreement provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2026 Revolving Credit Agreement. We had no amounts outstanding under the 2026 Revolving Credit Agreement as of June 30, 2026. We had no amounts outstanding under the 2021 Revolving Credit Agreement as of December 31, 2025. Refer to Note E Contractual Obligations and Commitments to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for additional information on the 2021 Revolving Credit Agreement. 364-Day Revolving Credit Agreement On February 26, 2026, we entered into a $2.000 billion 364-day revolving credit agreement (the 364-Day Revolving Credit Agreement) with a global syndicate of commercial banks. The 364-Day Revolving Credit Agreement matures on the date that is 364 days from the earlier of (i) the date that any loans under the 364-Day Revolving Credit Agreement are available to be drawn on, or (ii) the closing of our pending acquisition of Penumbra. Loans under the 364-Day Revolving Credit Agreement will bear interest at applicable base rates plus an applicable margin based on our credit ratings. In addition, we will pay a facility fee based on our credit rating and the total amount of revolving credit commitments (generally irrespective of usage), as well as a ticking fee based on the credit rating on the undrawn portion of the commitments, accruing from 120 days after the effective date of the 364-Day Revolving Credit Agreement. The 364-Day Revolving Credit Agreement contains substantially similar representations, warranties, covenants, events of default, and financial covenants as the 2026 Revolving Credit Agreement. We had no amounts outstanding under the 364-day Revolving Credit Agreement as of June 30, 2026. 364-Day Delayed Draw Term Loan Agreement On February 26, 2026, we entered into a $6.000 billion term loan credit agreement (the Term Loan Credit Agreement) with a global syndicate of commercial banks. The Term Loan Credit Agreement permits us to borrow (i) a 364-day delayed draw term loan in an aggregate principal amount of up to $1.000 billion (the Tranche A Loan), and (ii) a 364-day delayed draw term loan in an aggregate principal amount of up to $5.000 billion (the Tranche B Loan), in each case to fund our pending acquisition of Penumbra. Each of the Tranche A Loan and the Tranche B Loan may only be drawn upon the closing of our pending acquisition of Penumbra and will mature 364 days thereafter. Prior to the closing date of our pending acquisition of Penumbra, the Tranche B Loan commitments will be automatically reduced by an amount equal to net cash proceeds received from any equity issuance or debt incurrence, subject to certain exceptions. After the closing date of our pending acquisition of Penumbra, we are required to prepay any outstanding Tranche B Loans with the net cash proceeds of any subsequent equity issuance or debt incurrence, subject to certain exceptions. Loans under the Term Loan Credit Agreement will bear interest at applicable base rates, plus an applicable margin based on our credit ratings. In addition, we are required to pay a ticking fee based on the credit rating of the unused commitments, accruing from 120 days after the effective date of the Term Loan Credit Agreement, and will also pay a duration fee equal to 0.10% per annum on the aggregate outstanding principal amount of the Tranche B Loan, payable 90 days following the closing date of our pending acquisition of Penumbra. The Term Loan Credit Agreement contains substantially similar representations, warranties, covenants, events of default, and financial covenants as the 2026 Revolving Credit Agreement and 364-Day Revolving Credit Agreement. We had no amounts outstanding under the Term Loan Credit Agreement as of June 30, 2026. 22 Table of Contents Financial Covenant As of June 30, 2026, we were in compliance with the financial covenant required by our credit agreements described above. Covenant RequirementActual as of June 30, 2026as of June 30, 2026 Maximum permitted leverage ratio(1) 4.00 times2.02 times (in millions, except maturity and yield)June 30, 2026December 31, 2025 Commercial paper outstanding (at par)$1,689 $ Maximum borrowing capacity2,750 2,750 Borrowing capacity available 1,061 2,750 Weighted average maturity41 days0 days Weighted average yield4.06 % % 23 Table of Contents Senior Notes We had senior notes outstanding of $10.859 billion as of June 30, 2026 and $11.343 billion as of December 31, 2025. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (refer to Other Arrangements below). In February 2025, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of Boston Scientific, completed a registered public offering of 1.500 billion in aggregate principal amount of euro-denominated senior notes comprised of 850 million of 3.000% Senior Notes due 2031 and 650 million of 3.250% Senior Notes due 2034 (collectively, the 2025 Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the 2025 Eurobonds, in addition to all of AMS Europe's obligations under euro-denominated senior notes that were previously issued by AMS Europe in 2024 and 2022, and no other subsidiary of Boston Scientific will guarantee these obligations. AMS Europe is a finance subsidiary as defined in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The 2025 Eurobonds offering resulted in cash proceeds of $1.558 billion, net of investor discounts and issuance costs. We used the net proceeds from the 2025 Eurobonds offering to fund the repayment at maturity of AMS Europe s 1.000 billion 0.750% Senior Notes due March 2025 and to pay accrued and unpaid interest with respect to such notes. Additionally, we used the remaining net proceeds for general corporate purposes, including, among other things, short-term investments, reduction of short-term debt, funding of working capital and acquisitions. During the second quarter of 2025, we also repaid at maturity our $500 million 1.900% Senior Notes due June 2025 and accrued and unpaid interest with respect to such notes. Other Arrangements We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860, Transfers and Servicing. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net within our accompanying unaudited consolidated balance sheets, are aggregated by contract denominated currency below: (in millions, except interest rates)As of June 30, 2026As of December 31, 2025 Amount De-recognizedWeighted Average Interest RateAmount De-recognizedWeighted Average Interest Rate Euro denominated$159 4.7 %$193 3.6 % Yen denominated226 1.9 %230 1.4 % (in millions)June 30, 2026December 31, 2025 Trade accounts receivable$3,184 $3,058 Allowance for credit losses(135)(132) $3,049 $2,926 Inventories As of (in millions)June 30, 2026December 31, 2025 Finished goods$1,972 $1,849 Work-in-process277 246 Raw materials985 849 $3,235 $2,943 Property, plant and equipment, net As of (in millions)June 30, 2026December 31, 2025 Land$183 $173 Buildings and improvements2,715 2,484 Equipment, furniture and fixtures4,045 3,827 Capital in progress911 1,161 7,854 7,645 Less: accumulated depreciation3,728 3,610 $4,126 $4,036 NOTE G INCOME TAXES The following table provides a reconciliation of our reported tax rate to the rate from continuing operations: Three Months Ended June 30,Six Months Ended June 30, 2026202520262025 Reported tax rate14.6 %15.5 %(1.0)%16.0 % Impact of certain receipts/charges(1) 2.7 %2.9 %18.3 %2.2 % Rate from continuing operations17.3 %18.4 %17.4 %18.2 % (1) These receipts/charges are taxed at different rates than our rate from continuing operations. Our reported tax rate is affected by recurring items such as the amount of our earnings subject to differing tax rates in foreign jurisdictions and the impact of certain receipts and charges that are taxed at rates that differ from our rate from continuing operations. In the second quarter of 2026, the principal reason for the difference between our tax rate from continuing operations and our reported tax rate relates to discrete benefits primarily related to return-to-provision adjustments. 25 Table of Contents In the first six months of 2026, the principal reason for the difference between our tax rate from continuing operations and our reported tax rate relates to a discrete tax benefit of $384 million to reflect a change in the anticipated future tax rate at which we expect to recover certain capitalized expenses. In the second quarter and first six months of 2025, the principal reasons for the difference between our tax rate from continuing operations and our reported tax rate relates to certain acquisition-related net charges, and discrete tax benefits primarily related to stock-based compensation. As of June 30, 2026, we had $636 million of gross unrecognized tax benefits, of which a net $536 million, if recognized, would affect our effective tax rate. As of December 31, 2025, we had $596 million of gross unrecognized tax benefits, of which a net $501 million, if recognized, would affect our effective tax rate. The change in gross unrecognized tax benefits relates to accruals for current year positions. NOTE H COMMITMENTS AND CONTINGENCIES We are involved in various legal proceedings, including intellectual property, product liability, securities and commercial claims and disputes, employment matters, environmental matters, governmental inquiries, investigations and proceedings, and other legal matters that arise from time to time in the ordinary course of our business, including those described below. In recent years, we have successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters, however, there continues to be outstanding litigation and disputes. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity. Intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. From time to time, we face litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies. Product liability, securities, environmental and commercial claims have been asserted against us and similar or other claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability and environmental claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities, environmental and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity. In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local governmental agencies in the U.S. and other countries in which we operate. From time to time, we receive inquiries and have ongoing discussions with governmental agencies with respect to our operations, such as the Securities and Exchange Commission (SEC), the Department of Justice (DOJ) and other U.S. and foreign regulators. These include ongoing and any future investigations with respect to alleged Foreign Corrupt Practices Act (FCPA) violations, U.S.-based subpoenas and DOJ Civil Investigative Demands (CID), and qui tam actions or other governmental investigations often involving regulatory, marketing and other business practices. From time to time, we also self-disclose potential concerns to regulators. It is our standard practice to cooperate with governmental agencies when responding to such inquiries and investigating such matters. These governmental investigations and inquiries could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity. For additional information, refer to Note I Commitments and Contingencies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K. 26 Table of Contents In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. Our accrual for legal matters that are probable and estimable was $282 million as of June 30, 2026 and $242 million as of December 31, 2025 and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims and matters assumed from acquired companies. We record certain legal charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) within our accompanying unaudited consolidated financial statements. We recorded litigation-related net charges of $76 million during the second quarter and first six months of 2026 and did not record any litigation-related net charges (credits) during the second quarter and first six months of 2025. All other legal charges, credits and costs are recorded within Selling, general and administrative expenses within our accompanying unaudited consolidated statements of operations. We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant required by our credit arrangements. In management's opinion, we are not currently involved in any legal proceedings, other than those disclosed in our most recent Annual Report on Form 10-K and those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated. Patent Litigation On November 20, 2017, The Board of Regents, University of Texas System and TissueGen. Inc. (collectively, UT), served a lawsuit against us in the Western District of Texas. The complaint against the Company alleges patent infringement of two U.S. patents owned by UT, relating to Drug Releasing Biodegradable Fiber Implant and Drug Releasing Biodegradable Fiber for Delivery of Therapeutics, and affects the manufacture, use and sale of our Synergy Stent System. UT primarily seeks a reasonable royalty. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. In April 2020, the United States Supreme Court denied the UT s Petition for Certiorari. UT proceeded with its case against the Company in Delaware. In January 2023, a jury trial was held on the issue of whether the one UT patent still asserted in the case was valid and whether it was infringed by the Company. On January 31, 2023, a jury concluded that UT s patent was valid and willfully infringed by the Company, and awarded UT $42 million in damages. Following the trial, UT filed a motion seeking prejudgment interest and enhanced damages. The Company filed a motion seeking judgment as a matter of law in its favor or alternatively a new trial. On June 5, 2024, the Court granted the Company s motion for judgment as a matter of law of no willful infringement, but otherwise denied the Company s motions. The Court also denied UT s motion for enhanced damages, awarded approximately $7 million in pre-judgment interest, and awarded post-judgment interest. On July 3, 2024, UT and the Company each filed a notice of appeal. On July 27, 2026, the Court of Appeals for the Federal Circuit reversed, granting judgment as a matter of law in the Company s favor and finding UT s patent invalid and not infringed. Product Liability Litigation Multiple product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. We have entered into individual and master settlement agreements or are in the final stages of entering agreements with certain plaintiffs' counsel, to resolve the majority of these cases and claims. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. We have established a product liability accrual for remaining claims asserted against us associated with our transvaginal surgical mesh products and the costs of defense thereof. We continue to engage in discussions with plaintiffs counsel regarding potential resolution of pending cases and claims, which we continue to vigorously contest. The final resolution of the cases and 27 Table of Contents claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products. On February 20, 2026, counsel representing individuals claiming they have been injured by their spinal cord stimulation (SCS) devices filed a motion with the Judicial Panel on Multidistrict Litigation (JPML), seeking the transfer of various actions for coordinated or consolidated pretrial proceedings (In re: Abbott and Boston Scientific Spinal Cord Stimulator Products Liability Litigation, MDL No. 3181). On June 5, 2026, the JPML issued an order consolidating all pending and future federal SCS cases into one Multi-District Litigation in the Central District of California (In Re. Boston Scientific Corporation Spinal Cord Stimulator Products Liability Litigation, Case No. 2:26-ml-03181-JLS-E). The cases filed against the Company allege various injuries and damages arising from the Company s SCS products. Other Proceedings On March 5, 2026, purported Company shareholder John Rudolph Troike, individually and on behalf of all others similarly situated, filed a putative securities class action complaint in the United States District Court for the District of Massachusetts against the Company and certain current officers stemming from the drop in the Company s stock price on February 4, 2026 following the release of the Company s fourth quarter and full year 2025 results. The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 based on allegedly false and misleading statements concerning the Company s financial guidance and anticipated growth in the U.S. electrophysiology business unit. The complaint seeks, among other relief, unspecified compensatory damages, unspecified equitable relief, and costs and expenses. On May 20, 2026, the Court appointed the Indiana Public Retirement System as lead plaintiff. On July 20, 2026, plaintiffs filed an amended complaint, adding additional named plaintiffs Miami Fire Fighters and Police Officers Retirement Trust and Detroit General Retirement System, and additionally alleging violation of Section 20A of the Securities Exchange Act of 1934 against a current officer. On March 16, 2026, purported Company shareholder Greg Valen (the Valen Derivative Complaint ), and on April 23, 2026, purported Company shareholder Elliot Feder (the Feder Derivative Complaint ), and on July 9, 2026, purported Company shareholder Vladimir Gusinsky Revocable Trust (the Gusinsky Derivative Complaint ), and on July 10, 2026, purported Company shareholders Joseph Crognale and Feghali Foods, Inc. PSP (the Crognale Derivative Complaint ), each filed a shareholder derivative complaint in the United States District Court for the District of Massachusetts against the Company and certain current and former officers and directors, each containing substantially the same set of factual allegations as those asserted in the related securities class action case above, with the Gusinsky and Crognale Derivative Complaints also including allegations concerning the safety of batteries in the Company s Accolade products. Each complaint seeks, among other relief, unspecified compensatory damages, unspecified equitable relief, and costs and expenses. The Valen and Feder matters have been consolidated and stayed until the final resolution of the anticipated motion to dismiss in the related securities class action case. On March 23, 2026, the Company received a letter dated March 18, 2026, from a purported Company shareholder, Roberta Poznick, demanding that the Company s Board of Directors take action against certain current and former officers and directors and other unidentified individuals and entities relating to substantially the same set of factual allegations as those asserted in the related securities class action case above. NOTE I WEIGHTED AVERAGE SHARES OUTSTANDING Three Months Ended June 30,Six Months Ended June 30, (in millions)2026202520262025 Weighted average shares outstanding basic1,470.2 1,479.9 1,477.6 1,478.5 Net effect of common stock equivalents4.6 13.7 7.4 14.8 Weighted average shares outstanding - diluted1,474.8 1,493.5 1,484.9 1,493.3 28 Table of Contents The following securities were excluded from the calculation of weighted average shares outstanding - diluted because their effect in the periods presented below would have been antidilutive: Three Months Ended June 30,Six Months Ended June 30, (in millions)2026202520262025 Stock options outstanding(1) 5131 (1) Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods. We base Net income (loss) per common share - diluted upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options and stock awards from the calculation if the effect would be anti-dilutive. We issued less than one million shares of our common stock in the second quarter of 2026, approximately four million shares of our common stock in the first six months of 2026, approximately one million shares in the second quarter of 2025 and approximately six million shares in the first six months of 2025. Shares were issued following the exercise of stock options, vesting of restricted stock units or purchases under our employee stock purchase plan. Share Repurchase On February 18, 2026, our Board of Directors approved a $4.000 billion increase to our existing authorization to repurchase up to $1.000 billion of our common stock, increasing the total repurchase authorization to $5.000 billion. On May 18, 2026, we entered into an accelerated share repurchase agreement (the ASR agreement) with JPMorgan Chase Bank, National Association (JPMorgan), to repurchase $2.000 billion of our common stock. On May 19, 2026, under the terms of the ASR agreement, we made an aggregate upfront payment of $2.000 billion to JPMorgan and received an initial delivery of approximately 30 million shares of our common stock, representing approximately 80 percent of the transaction value based on the closing price of our common stock on May 15, 2026. The final settlement occurred on June 12, 2026, and we received approximately 10 million additional shares of our common stock. The total number of shares repurchased under the ASR agreement was based on the volume-weighted average price of our common stock during the repurchase period, less adjustments pursuant to the terms and conditions of the ASR agreement. The total number of shares repurchased under the ASR agreement are held as treasury stock within our accompanying unaudited consolidated balance sheets. As of June 30, 2026, we had $3.000 billion remaining available under the share repurchase authorization. We did not repurchase any shares of our common stock in the first six months of 2025. The initial repurchase of our common stock and final settlement reduced the weighted average shares outstanding used to calculate basic and diluted earnings per share. The initial repurchase of our common stock was accounted for as a reduction of stockholders equity within our accompanying unaudited consolidated balance sheets. The remainder was accounted for as an unsettled forward contract indexed to our common stock until the final settlement occurred. The forward contract was classified as equity through the final settlement date in accordance with FASB ASC Topic 815. NOTE J SEGMENT REPORTING We aggregate our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. In accordance with FASB ASC Topic 280, Segment Reporting, we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments. In the fourth quarter of 2025, we reorganized our operating segments; this change had no impact on our reportable segments. Our chief operating decision maker (CODM) is our President and Chief Executive Officer. 29 Table of Contents We measure and evaluate our reportable segments based on their respective net sales, cost of goods sold, selling, general and administrative expenses, research and development expenses, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all based on internally-derived standard currency exchange rates to exclude the impact of foreign currency, which may be updated from year to year. We exclude from segment expenses and segment operating income certain corporate-related expenses and certain transactions or adjustments that our CODM considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), European Union (EU) Medical Device Regulation (MDR) implementation costs, and the International Emergency Economic Powers Act (IEEPA) tariff refund. Although we exclude these amounts from segment expenses and segment operating income, they are included in reported Income (loss) before income taxes within our accompanying unaudited consolidated statements of operations and are included in the reconciliation below. The CODM uses segment operating income in the strategic plan, annual operating plan and other forecasting cycles. During these forecasting cycles, the CODM compares budget versus actual results to evaluate both internal and external events and conditions, which are used in assessing the performance of the reportable segments and to allocate resources across our reportable segments. Refer to Note K Revenue for net sales by reportable segment presented in accordance with GAAP. A reconciliation of sales and operating income for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows. Prior period amounts have been restated at constant currency to conform to current year presentation. Three Months Ended June 30, 2026 (in millions, except percentages) MedSurg% of Net Sales Cardiovascular% of Net Sales Total Net sales of reportable segments$1,818 $3,622 $5,440 Impact of foreign currency fluctuations2 Total net sales$5,442 Segment expenses: Cost of products sold526 28.9 %1,065 29.4 % Selling, general and administrative expenses567 31.2 %992 27.4 % Research and development expenses124 6.8 %359 9.9 % Other segment items(1) 4 0.2 %8 0.2 % Segment operating income(2) 598 32.9 %1,197 33.1 %1,795 Unallocated amounts: Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(252) Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), EU MDR implementation costs, and the IEEPA tariff refund (132) Amortization expense(233) Operating income (loss) 1,178 Other income (expense), net(118) Income (loss) before income taxes$1,060 30 Table of Contents Three Months Ended June 30, 2025 (in millions, except percentages) MedSurg% of Net Sales Cardiovascular% of Net Sales Total Net sales of reportable segments$1,725 $3,365 $5,090 Impact of foreign currency fluctuations(29) Total net sales$5,061 Segment expenses: Cost of products sold470 27.3 %1,048 31.2 % Selling, general and administrative expenses521 30.2 %915 27.2 % Research and development expenses120 7.0 %316 9.4 % Other segment items(1) 8 0.4 %6 0.2 % Segment operating income(2) 606 35.1 %1,079 32.1 %1,685 Unallocated amounts: Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(286) Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs (355) Amortization expense(225) Operating income (loss) 819 Other income (expense), net122 Income (loss) before income taxes$941 31 Table of Contents Six months ended June 30, 2026 (in millions, except percentages) MedSurg% of Net Sales Cardiovascular% of Net Sales Total Net sales of reportable segments$3,518 $7,124 $10,643 Impact of foreign currency fluctuations3 Total net sales$10,646 Segment expenses: Cost of products sold1,004 28.5 %2,133 29.9 % Selling, general and administrative expenses1,124 31.9 %1,952 27.4 % Research and development expenses251 7.1 %702 9.9 % Other segment items(1) 9 0.3 %15 0.2 % Segment operating income(2) 1,130 32.1 %2,323 32.6 %3,453 Unallocated amounts: Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(451) Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), EU MDR implementation costs, and the IEEPA tariff refund (258) Amortization expense(466) Operating income (loss) 2,279 Other income (expense), net(57) Income (loss) before income taxes$2,222 32 Table of Contents Six months ended June 30, 2025 (in millions, except percentages) MedSurg% of Net Sales Cardiovascular% of Net Sales Total Net sales of reportable segments$3,335 $6,522 $9,856 Impact of foreign currency fluctuations(133) Total net sales$9,724 Segment expenses: Cost of products sold906 27.2 %1,975 30.3 % Selling, general and administrative expenses1,033 31.0 %1,788 27.4 % Research and development expenses241 7.2 %600 9.2 % Other segment items(1) 13 0.4 %12 0.2 % Segment operating income(2) 1,142 34.2 %2,148 32.9 %3,290 Unallocated amounts: Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(541) Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs (564) Amortization expense(444) Operating income (loss) 1,740 Other income (expense), net6 Income (loss) before income taxes$1,746 (1) Includes royalty expense. (2) Calculated as Net sales of reportable segments less Segment expenses. Three Months Ended June 30,Six Months Ended June 30, Depreciation expense (in millions) 2026202520262025 MedSurg$29 $28 $57 $55 Cardiovascular93 83 183 162 Consolidated depreciation expense$122 $111 $240 $217 As of Total assets (in millions) June 30, 2026December 31, 2025 MedSurg$3,804 $3,392 Cardiovascular8,455 7,999 Total assets of reportable segments12,259 11,391 18,640 18,282 Other intangible assets, net6,918 7,019 All other corporate assets7,398 6,981 $45,216 $43,673 33 Table of Contents As of Long-lived assets (in millions) June 30, 2026December 31, 2025 U.S.$1,984 $1,919 Ireland752 750 Costa Rica647 637 Other countries743 730 Property, plant and equipment, net4,126 4,036 Goodwill18,640 18,282 Other intangible assets, net6,918 7,019 Operating lease right-of-use assets in Other long-term assets 553 465 $30,237 $29,802 NOTE K REVENUE We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our accompanying unaudited consolidated statements of operations. In the fourth quarter of 2025, we reorganized our business structure into four operating segments. The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated. We have revised prior periods to conform to current year presentation. Three Months Ended June 30, 20262025 BusinessesU.S.Int'lTotalU.S.Int'lTotal Endoscopy$491 $303 $793 $456 $281 $737 Urology503 181 684 499 178 676 Neuromodulation257 84 341 228 75 303 MedSurg1,251 567 1,818 1,183 534 1,716 Interventional Cardiology & Vascular Therapies586 746 1,333 499 679 1,178 Watchman459 48 507 446 40 486 Electrophysiology606 310 916 587 252 840 Cardiac Rhythm Management349 236 585 355 235 590 Interventional Oncology & Embolization175 108 283 155 96 251 Cardiovascular2,175 1,449 3,624 2,042 1,303 3,345 Total Net Sales$3,426 $2,017 $5,442 $3,224 $1,837 $5,061 34 Table of Contents Six Months Ended June 30, 20262025 BusinessesU.S.Int'lTotalU.S.Int'lTotal Endoscopy$937 $593 $1,529 $876 $534 $1,410 Urology967 363 1,330 967 342 1,310 Neuromodulation494 166 659 432 142 574 MedSurg2,398 1,121 3,519 2,275 1,018 3,293 Interventional Cardiology & Vascular Therapies1,139 1,438 2,577 966 1,337 2,302 Watchman921 93 1,014 836 75 911 Electrophysiology1,209 612 1,821 1,099 472 1,570 Cardiac Rhythm Management698 465 1,163 713 455 1,168 Interventional Oncology & Embolization344 207 551 296 183 479 Cardiovascular4,311 2,815 7,126 3,909 2,521 6,430 Total Net Sales$6,709 $3,936 $10,646 $6,185 $3,539 $9,724 Refer to Note J Segment Reporting for information on our reportable segments. Three Months Ended June 30,Six Months Ended June 30, Geographic Regions2026202520262025 U.S.$3,426 $3,224 $6,709 $6,185 Europe, Middle East and Africa932 878 1,864 1,725 Asia-Pacific878 790 1,682 1,491 Latin America and Canada206 169 391 324 Total Net Sales$5,442 $5,061 $10,646 $9,724 Deferred Revenue Contract liabilities are classified as Other current liabilities and Other long-term liabilities within our accompanying unaudited consolidated balance sheets. Our deferred revenue balance was $691 million as of June 30, 2026 and $682 million as of December 31, 2025. Our contract liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System within our Cardiovascular business, for which revenue is recognized over the average service period based on device and patient longevity. Our contract liabilities also include deferred revenue related to the LUX-Dx II+ Insertable Cardiac Monitor system, also within our Cardiovascular business, for which revenue is recognized over the average service period based on device longevity and usage. Variable Consideration For additional information on variable consideration, refer to Note A Significant Accounting Policies to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K. 35 Table of Contents NOTE L CHANGES IN OTHER COMPREHENSIVE INCOME The following tables provide the reclassifications out of Other comprehensive income (loss), net of tax attributable to Boston Scientific common stockholders: Foreign Currency Translation AdjustmentNet Change in Derivative Financial InstrumentsTotal Balance as of March 31, 2026$(428)$31 (1)$(399) Other comprehensive income (loss) before reclassifications85 12 97 (Income) loss amounts reclassified from accumulated other comprehensive income(6)3 (3) Total other comprehensive income (loss)80 15 94 Balance as of June 30, 2026$(349)$46 (1)$(304) Foreign Currency Translation AdjustmentNet Change in Derivative Financial InstrumentsTotal Balance as of March 31, 2025$(80)$69 (17)$(28) Other comprehensive income (loss) before reclassifications(474)(198)(671) (Income) loss amounts reclassified from accumulated other comprehensive income(7)(16)(23) Total other comprehensive income (loss)(480)(214)(694) Balance as of June 30, 2025$(560)$(145)(17)$(722) Foreign Currency Translation AdjustmentNet Change in Derivative Financial InstrumentsTotal Balance as of December 31, 2025$(561)$(48)(2)$(610) Other comprehensive income (loss) before reclassifications220 88 309 (Income) loss amounts reclassified from accumulated other comprehensive income(8)5 (3) Total other comprehensive income (loss)212 93 305 Balance as of June 30, 2026$(349)$46 (1)$(304) Foreign Currency Translation AdjustmentNet Change in Derivative Financial InstrumentsTotal Balance as of December 31, 2024$136 $155 (16)$275 Other comprehensive income (loss) before reclassifications(686)(252)(938) (Income) loss amounts reclassified from accumulated other comprehensive income(11)(47)(58) Total other comprehensive income (loss)(696)(300)(996) Balance as of June 30, 2025$(560)$(145)(17)$(722) Refer to Note D Hedging Activities and Fair Value Measurements for further detail on our net investment hedges recorded in Foreign currency translation adjustment and our cash flow hedges recorded in Net change in derivative financial instruments. 36 Table of Contents NOTE M - RESTRUCTURING-RELATED ACTIVITIES On July 21, 2026, our Board of Directors approved, and we committed to, a new global restructuring program (the 2026 Restructuring Plan). The 2026 Restructuring Plan is intended to support our efforts to drive sustained cost efficiencies and enable continued growth by ensuring that we are structured and resourced to support our strategic priorities. Key activities under the 2026 Restructuring Plan will include supply chain optimization, including transferring certain production lines among facilities, targeted functional transformation and organizational structure evolution to drive sustained cost efficiencies. These activities are expected to be initiated in 2026 and to be substantially completed by the end of 2029. While new jobs are created in areas of growth and resources are deployed to support our portfolio and global market needs, we do expect some headcount reductions to result from these restructuring activities. The implementation of the 2026 Restructuring Plan is estimated to result in total pre-tax charges of approximately $700 million to $800 million, of which approximately $600 million to $700 million is expected to result in future cash outlays, and reduce gross annual pre-tax expenses by approximately $500 million as program benefits are realized. We expect a substantial portion of the savings to be reinvested in strategic growth initiatives. The following table provides a summary of our estimates of total pre-tax charges associated with the 2026 Restructuring Plan by major type of cost: Type of Cost (in millions) Total Estimated Amount Expected to be Incurred $300 -$350 Termination benefits(2) 275 -300 Other(3) 125 -150 $700 -$800 (1) Represents costs to transfer product manufacturing lines between geographically dispersed facilities. (2) Plans detailing specific employee impacts will be developed for each affected region and business, working with employee representative bodies where required under local laws. (3) Consists of consulting fees and costs associated with contractual cancellations as well as other costs directly related to the restructuring program, including program management, accelerated depreciation and fixed asset write-offs. NOTE N NEW ACCOUNTING PRONOUNCEMENTS Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our accompanying unaudited consolidated financial statements. Standards to be Implemented In November 2024, the FASB issued ASC Update No. 2024-03 Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. Update No. 2024-03 aims to improve transparency of expense disclosures to enhance investor understanding of an entity's performance and to assist in comparing an entity's performance over time and with that of other entities. Update No. 2024-03 modifies the disclosures over certain costs and expenses and requires entities to disclose (1) the amounts of purchases of inventory, employee compensation, depreciation, intangible asset amortization, and depletion, included in each relevant expense caption, (2) within the same disclosure, certain amounts that are already required to be disclosed under current GAAP, (3) a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively and (4) the total amount of selling expenses and, in annual reporting periods, an entity s definition of selling expenses. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Update No. 2024-03 allows for early adoption and requires either prospective adoption to financial statements issued for reporting periods after the effective date, or retrospectively to any or all prior periods presented in the financial statements. We are currently assessing the impact of Update No. 2024-03 to our unaudited consolidated financial statements. In September 2025, the FASB issued ASC Update No. 2025-06 Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. Update No. 2025-06 modernizes the accounting for software costs by removing all references to a sequential software development method, requiring entities to 37 Table of Contents begin capitalizing software costs when (1) management has authorized and committed to funding the software project, and (2) it is probable that the project will be completed and the software will be used for its intended purpose. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Update No. 2025-06 allows for early adoption and permits either a prospective, modified prospective, or retrospective adoption approach. We do not expect the adoption of Update No. 2025-06 to have a material impact to our unaudited consolidated financial statements. In September 2025, the FASB issued ASC Update No. 2025-07 Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (606): Derivatives scope refinements and scope clarification for share-based noncash consideration from a customer in a revenue contract. Update No. 2025-07 clarifies the application of derivative accounting to certain contracts and refines the guidance for share-based noncash consideration received from customers. Specifically, Update No. 2025-07 introduces a scope exception for contracts that are not exchange-traded and whose underlying is tied to operations or activities specific to one of the parties to the contract. It also clarifies that share-based noncash consideration from a customer should initially be accounted for under Topic 606 until the right to receive or retain such consideration becomes unconditional. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. Update No. 2025-07 allows for early adoption and the amendments can be applied either prospectively or on a modified retrospective basis through a cumulative-effect adjustment to the opening balance of retained earnings. We do not expect the adoption of Update No. 2025-07 to have a material impact to our unaudited consolidated financial statements. No other new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our accompanying unaudited consolidated financial statements. 38 Table of Contents ITEM 2.MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Introduction Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. As a medical technology leader for more than 45 years, we have advanced the practice of less-invasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the body. We advance science for life by providing a broad range of high-performance solutions to address unmet patient needs and reduce the cost of healthcare. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. Executive Summary The following section describes some of our financial highlights and trends on a consolidated basis. For additional information on our business units and product offerings, refer to Item 1. Business of our most recent Annual Report on Form 10-K. (in millions, except percentages and per share data)Three Months Ended June 30,2026 versus 20252026 versus 2025 20262025$% Reported net sales$5,442 $5,061 $381 7.5 % Reported net income (loss) attributable to Boston Scientific common stockholders907 797 110 13.8 % Adjusted net income (loss) attributable to Boston Scientific common stockholders (non-GAAP measure) 1,275 1,127 148 13.1 % Net income (loss) per common share diluted0.61 0.53 0.08 15.2 % Adjusted net income (loss) per common share diluted (non-GAAP measure) 0.86 0.75 0.11 14.6 % (in millions, except percentages and per share data)Six Months Ended June 30,2026 versus 20252026 versus 2025 20262025$% Reported net sales$10,646 $9,724 $922 9.5 % Reported net income (loss) attributable to Boston Scientific common stockholders2,247 1,471 776 52.8 % Adjusted net income (loss) attributable to Boston Scientific common stockholders (non-GAAP measure) 2,464 2,248 216 9.6 % Net income (loss) per common share diluted1.51 0.98 0.53 53.6 % Adjusted net income (loss) per common share diluted (non-GAAP measure) 1.66 1.51 0.15 10.2 % Three Months Ended June 30,Six Months Ended June 30, 2026 versus 20252026 versus 2025 Net sales reported growth7.5 %9.5 % Impact of foreign currency fluctuations(0.5)%(1.4)% Net sales operational growth (non-GAAP measure)7.0 %8.1 % Impact of certain acquisitions and divestitures % % Net sales organic growth (non-GAAP measure)7.0 %8.1 % 39 Table of Contents During the second quarter and first six months of 2026, the increase in our reported net sales was primarily driven by innovation and strong commercial execution in our Interventional Cardiology and Vascular Therapies and Electrophysiology business units. Refer to Results of Operations for a discussion of our net sales by business. During the second quarter of 2026, the increase in our reported net income attributable to Boston Scientific common stockholders was primarily driven by higher net sales. During the first six months of 2026, the increase in our reported net income attributable to Boston Scientific common stockholders was primarily driven by higher net sales and a discrete tax benefit recorded in the first quarter of 2026. Refer to Tax Rate for additional details pertaining to the discrete tax benefit. To supplement our unaudited consolidated financial statements prepared on a generally accepted accounting principles in the United States (GAAP) basis, we disclose certain non-GAAP measures, including operational and organic net sales growth, adjusted net income attributable to Boston Scientific common stockholders and adjusted net income per common share - diluted. Operational net sales growth excludes the impact of foreign currency fluctuations. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. There were no applicable acquisitions in the first six months of 2026 or 2025. Our adjusted net income attributable to Boston Scientific common stockholders and adjusted net income per common share - diluted exclude certain charges and/or credits as reported in our net income attributable to Boston Scientific common stockholders and net income per common share - diluted for purposes of assessing operating performance. Adjusted measures, including operational and organic net sales growth, adjusted net income attributable to Boston Scientific common stockholders and adjusted net income per common share - diluted, exclude certain items required by GAAP, are not prepared in accordance with GAAP and should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP measure. Refer to Additional Information for a discussion of management s use of these non-GAAP financial measures. Macroeconomic Environment Our business is affected by global macroeconomic and geopolitical conditions. There continues to be significant uncertainty with respect to global trade policies, including changing tariff rates, tariff imposition delays, and the potential for reciprocal restrictive trade policies by the U.S. or other governments around the world, which could adversely impact our operations and results. We may also experience higher distribution costs and supply chain disruptions, including those arising from global conflicts and energy market volatility. While we seek to mitigate these impacts, their extent and duration remain uncertain and could negatively impact our business and results of operations. For additional information, refer to Item 1A. Risk Factors and Macroeconomic Environment contained in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of our most recent Annual Report on Form 10-K. Results of Operations Net Sales The following section describes our net sales by reportable segment and business. In the fourth quarter of 2025, an organizational change combined our legacy Cardiology and Peripheral Interventions businesses into a single Cardiovascular business. We have revised prior periods to conform to the current year presentation. The change had no impact on our reportable segments. For additional information on our business units and product offerings, refer to Item 1. Business of our most recent Annual Report on Form 10-K. Increase/(Decrease) (in millions, except percentages)Three Months Ended June 30,$Reported BasisImpact of Foreign Currency FluctuationsOperational BasisImpact of Certain Acquisitions / Divestitures(1) Organic Basis 20262025 Endoscopy$793$737$56 7.6 %(0.7)%7.0 % %7.0 % Urology6846767 1.1 %(0.3)%0.8 % %0.8 % Neuromodulation34130339 12.7 %(0.6)%12.2 % %12.2 % MedSurg1,8181,716102 5.9 %(0.5)%5.4 % %5.4 % Cardiovascular3,6243,345279 8.3 %(0.6)%7.8 % %7.8 % Net Sales$5,442$5,061$381 7.5 %(0.5)%7.0 % %7.0 % 40 Table of Contents Increase/(Decrease) (in millions, except percentages)Six Months Ended June 30,$Reported BasisImpact of Foreign Currency FluctuationsOperational BasisImpact of Certain Acquisitions / Divestitures(1) Organic Basis 20262025 Endoscopy$1,529$1,410$119 8.5 %(1.6)%6.9 % %6.9 % Urology1,3301,31021 1.6 %(0.9)%0.6 % %0.6 % Neuromodulation65957486 14.9 %(1.2)%13.7 % %13.7 % MedSurg3,5193,293226 6.9 %(1.3)%5.6 % %5.6 % Cardiovascular7,1266,430696 10.8 %(1.4)%9.4 % %9.4 % Net Sales$10,646$9,724$922 9.5 %(1.4)%8.1 % %8.1 % (1) There were no applicable acquisitions in the second quarter and first six months of 2026 or 2025. MedSurg Endoscopy Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) conditions with innovative, less-invasive technologies. In the second quarter and first six months of 2026, reported net sales growth was primarily driven by our biliary franchise, led by our AXIOS Stent and Delivery System, and our core GI franchise. Urology Our Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction and incontinence. In the second quarter and first six months of 2026, reported net sales growth was relatively flat, primarily driven by underperformance in our stone franchise as a result of volume-based-procurement in China, and commercial disruption in our sacral neuromodulation franchise. Neuromodulation Our Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. In the second quarter and first six months of 2026, reported net sales growth was primarily driven by our comprehensive pain portfolio, led by our Intracept Intraosseous Nerve Ablation System and Nalu Peripheral Nerve Stimulation System, and our deep brain stimulation franchise. Cardiovascular Our Cardiovascular business develops and manufactures devices and medical technologies for diagnosing and treating a variety of diseases and abnormalities of the heart, as well as products to diagnose and treat peripheral arterial and venous diseases and various forms of cancer. In the second quarter and first six months of 2026, reported net sales growth was primarily driven by our coronary therapies franchise, led by our AGENT Drug-Coated Balloon, and our Electrophysiology business unit, led by our Farapulse Pulsed Field Ablation (PFA) System. Net sales for the second quarter and first six months of 2026 were impacted by increased competition within our Electrophysiology business unit and a deceleration of certain WATCHMAN procedures. 41 Table of Contents Gross Profit Our gross profit was $3.848 billion during the second quarter of 2026, $3.424 billion during the second quarter of 2025, $7.462 billion for the first six months of 2026, and $6.633 billion for the first six months of 2025. The following is a reconciliation of our gross profit margin and a description of the drivers of the changes from period to period: Three MonthsSix Months Period ended June 30, 202567.7%68.2% 0.6%0.7% Net impact of foreign currency fluctuations(0.4)%(0.6)% All other, including inventory charges and other period expenses2.9%1.8% Period ended June 30, 202670.7%70.1% In the second quarter of 2026, the primary factors that impacted gross profit margin were increased sales of higher margin products, the benefit recognized in connection with the recovery of previously incurred tariffs and a decrease in inventory charges, slightly offset by an unfavorable impact from foreign currency. These factors also impacted gross profit margin during the first six months of 2026, along with a decrease in the impact of inventory step-up adjustments associated with acquisitions. Operating Expenses The following table provides a summary of our key operating expenses: Three Months Ended June 30,Six Months Ended June 30, 2026202520262025 (in millions, except percentages)$% of Net Sales$% of Net Sales$% of Net Sales$% of Net Sales Selling, general and administrative expenses$1,803 33.1 %$1,716 33.9 %$3,583 33.7 %$3,312 34.1 % Research and development expenses554 10.2 %526 10.4 %1,069 10.0 %969 10.0 % Six Months Ended June 30, 202620252026 versus 20252026 versus 2025202620252026 versus 20252026 versus 2025 (in millions, except percentages)$%$% Amortization expense$233 $225 $8 3.4 %$466 $444 $21 4.8 % Total Amount Incurred $357 Termination benefits(2) 115 Other(3) 276 $748 (1) Represents costs to transfer product manufacturing lines between geographically dispersed facilities. (2) Plans detailing specific employee impacts are developed for each affected region and business, working with employee representative bodies where required under local laws. (3) Consists of consulting fees and costs associated with contractual cancellations as well as other costs directly related to the restructuring program, including program management, impairment of right of use lease assets, accelerated depreciation and fixed asset write-offs. The following table presents our restructuring and restructuring-related net charges: Three Months Ended June 30,Six Months Ended June 30, (in millions)2026202520262025 Restructuring net charges (credits)(1) $8 $83 $11 $93 Restructuring-related net charges (credits)(2) 33 78 66 117 (1) These charges are recorded in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 420, Exit or Disposal Cost Obligations. (2) These charges are primarily recorded within Cost of products sold, SG&A Expenses and R&D Expenses. The following table presents our restructuring reserve balance: (in millions)June 30, 2026December 31, 2025$33 $59 Six Months Ended June 30, (in millions)2026202520262025 Interest income$11 $3 $26 $9 Net foreign currency gain (loss)(15)(0)(26)(1) Net gains (losses) on investments(1) (12)220 146 193 Other income (expense), net(6)(10)(17)(22) $(23)$213 $129 $179 (1) Net gains (losses) on investments include investment portfolio net losses (gains) and impairments as well as the impact of recording our share of the earnings or losses of equity method investees. During the second quarter of 2026, the decrease in Other, net, compared to the prior year period, was primarily driven by the gain associated with the remeasurement of our previously held investment in Bolt Medical, Inc. (Bolt Medical) to fair value based on the allocation of the acquisition purchase price when we acquired the remaining shares of Bolt Medical in the second quarter of 2025. Tax Rate The following table provides a reconciliation of our reported tax rate to the rate from continuing operations: Three Months Ended June 30,Six Months Ended June 30, 2026202520262025 Reported tax rate14.6 %15.5 %(1.0)%16.0 % Impact of certain receipts/charges(1) 2.7 %2.9 %18.3 %2.2 % Rate from continuing operations17.3 %18.4 %17.4 %18.2 % (1) These receipts/charges are taxed at different rates than our rate from continuing operations. Our reported tax rate is affected by recurring items such as the amount of our earnings subject to differing tax rates in foreign jurisdictions and the impact of certain receipts and charges that are taxed at rates that differ from our rate from continuing operations. In the second quarter of 2026, the principal reason for the difference between our tax rate from continuing operations and our reported tax rate relates to discrete benefits primarily related to return-to-provision adjustments. In the first six months of 2026, the principal reason for the difference between our tax rate from continuing operations and our reported tax rate relates to a discrete tax benefit of $384 million to reflect a change in the anticipated future tax rate at which we expect to recover certain capitalized expenses. In the second quarter and first six months of 2025, the principal reasons for the difference between our tax rate from continuing operations and our reported tax rate relates to certain acquisition-related net charges, and discrete tax benefits primarily related to stock-based compensation. We completed our assessment of the One Big Beautiful Bill Act (OBBBA) and related administrative guidance issued to date during the second quarter of 2026. Based on our evaluation, OBBBA did not have a material impact on our tax rate from continuing operations. We will continue to monitor future legislative and regulatory developments. Any future legislative guidance could change our assessment of the impact of OBBBA on our tax rate from continuing operations. We also continue to evaluate developments related to the Pillar Two framework issued by the Organization for Economic Cooperation and Development (OECD) and to refine its assessment of the application of the framework and the administrative guidance during the quarter. The impact of the Pillar Two global minimum tax on our tax rate from continuing operations was immaterial in the second quarter of 2026. 44 Table of Contents We continue to monitor legislative adoption by each member country of the OECD s January 5, 2026 administrative guidance that introduced new safe harbors for U.S.-based multinational companies. While adoption of these safe harbors is important to achieve certainty regarding the exemption of U.S.-based multinational companies and their subsidiaries from certain elements of the OECD global minimum tax framework in 2026, we do not currently expect the legislative adoption of such guidance to have a material impact on our tax rate from continuing operations. See Note G Income Taxes to our unaudited consolidated financial statements included in Part I, Item 1 of this Quarterly Report for additional details on our tax rate. Critical Accounting Policies and Estimates Our financial results are affected by the selection and application of accounting policies and methods. During the second quarter and first six months of 2026, there were no material changes to the application of critical accounting policies previously disclosed in our most recent Annual Report on Form 10-K. Liquidity and Capital Resources Based on our current business plan, we believe our existing balance of Cash and cash equivalents, future cash generated from operations, access to capital markets and existing credit facilities will be sufficient to fund our operations, invest in our infrastructure, pay our legal-related liabilities, pay taxes due, service and repay our existing debt and fund possible acquisitions for the next 12 months and for the foreseeable future. For additional information on our future payment obligations and commitments, refer to Contractual Obligations and Commitments below and contained in Item 7 of our most recent Annual Report on Form 10-K. As of June 30, 2026, we had $539 million of unrestricted Cash and cash equivalents on hand. The balance is comprised of $130 million invested in money market funds and time deposits and $409 million in interest bearing and non-interest-bearing bank accounts. We invest excess cash on hand in short-term financial instruments that earn market interest rates while mitigating principal risk through instrument and counterparty diversification, as well as what we believe to be prudent instrument selection. We limit our direct exposure to securities in any one industry or issuer. On February 26, 2026, we entered into a new $3.000 billion revolving credit agreement (the 2026 Revolving Credit Agreement) with a global syndicate of commercial banks and terminated our previous revolving credit agreement (the 2021 Revolving Credit Agreement). The 2026 Revolving Credit Agreement matures on February 26, 2031, with one-year extension options subject to certain conditions, including certain lender approvals. This credit agreement provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2026 Revolving Credit Agreement. As of June 30, 2026, there was $1.689 billion outstanding under our commercial paper program and no amounts outstanding under the 2026 Revolving Credit Agreement, resulting in an additional $1.311 billion of available liquidity. On February 26, 2026, we entered into a $2.000 billion 364-day revolving credit agreement (the 364-Day Revolving Credit Agreement) with a global syndicate of commercial banks. The 364-Day Revolving Credit Agreement matures on the date that is 364 days from the earlier of (i) the date that any loans under the 364-Day Revolving Credit Agreement are available to be drawn on, or (ii) the closing of our pending acquisition of Penumbra, Inc. (Penumbra). In addition, on February 26, 2026, we entered into a $6.000 billion term loan credit agreement (the Term Loan Credit Agreement) with a global syndicate of commercial banks. The Term Loan Credit Agreement permits us to borrow (i) a 364-day delayed draw term loan in an aggregate principal amount of up to $1.000 billion (the Tranche A Loan), and (ii) a 364-day delayed draw term loan in an aggregate amount of up to $5.000 billion (the Tranche B Loan). Each of the Tranche A Loan and the Tranche B Loan may only be drawn upon the closing of our pending acquisition of Penumbra and will mature 364 days thereafter. As of June 30, 2026, we had no amounts outstanding under the 364-Day Revolving Credit Agreement or Term Loan Credit Agreement. For additional details related to our debt obligations, including our financial covenant requirement, refer to Note E Contractual Obligations and Commitments to our unaudited consolidated financial statements contained in Part I, Item 1 of this Quarterly Report. On July 21, 2026, our Board of Directors approved, and we committed to, a new global restructuring program. For additional information on the new restructuring plan, refer to Note M - Restructuring-Related Activities to our unaudited consolidated financial statements contained in Part I, Item 1 of this Quarterly Report. 45 Table of Contents The following provides a summary and description of our net cash inflows (outflows): Six Months Ended June 30, (in millions)20262025 Cash provided by (used for) operating activities$1,822 $1,827 Cash provided by (used for) investing activities(2,547)(1,626) Cash provided by (used for) financing activities(670)(107) Operating Activities During the first six months of 2026, cash provided by (used for) operating activities remained relatively flat compared to the prior year period primarily due to comparatively higher sales and corresponding operating income, offset by an increase in employee and working capital-related payments. Investing Activities During the first six months of 2026, cash provided by (used for) investing activities included net cash payments of $718 million for acquisitions of multiple businesses, primarily related to Nalu Medical, Inc., net payments for investments and acquisitions of certain technologies of $1.501 billion, primarily related to the investment in MiRus LLC (MiRus), and purchases of property, plant and equipment and internal use software of $372 million. For more information on our acquisitions and the investment in MiRus, refer to Note B Acquisitions and Strategic Investments to our unaudited consolidated financial statements contained in Part I, Item 1 of this Quarterly Report. During the first six months of 2025, cash provided by (used for) investing activities included net cash payments of $1.248 billion for acquisitions of multiple businesses, primarily related to Bolt Medical, Inc., SoniVie Ltd. and Cortex, Inc., and purchases of property, plant and equipment and internal use software of $344 million. Financing Activities During the first six months of 2026, cash provided by (used for) financing activities included net proceeds from the issuance of commercial paper of $1.675 billion, a $2.000 billion payment to repurchase shares of our common stock, and a $255 million payment of the remaining balance of 3.750% Senior Notes due March 2026. For more information on our borrowings, refer to Note E Contractual Obligations and Commitments to our unaudited consolidated financial statements contained in Part I, Item 1 of this Quarterly Report. For more information on our share repurchase, refer to Note I Weighted Average Shares Outstanding to our unaudited consolidated financial statements contained in Part I, Item 1 of this Quarterly Report. Cash provided by (used for) financing activities in the first six months of 2025 included the registered public offering of 1.500 billion in aggregate principal amount of euro-denominated senior notes (the 2025 Eurobonds). The 2025 Eurobonds offering resulted in cash proceeds of $1.558 billion, net of investor discounts and issuance costs. We used the net proceeds from the 2025 Eurobonds offering to fund the repayment at maturity of AMS Europe s 1.000 billion 0.750% Senior Notes due March 2025 and to pay accrued and unpaid interest with respect to such notes. Additionally, we used the remaining net proceeds for general corporate purposes, including, among other things, short-term investments, reduction of short-term debt, funding of working capital and acquisitions. During the second quarter of 2025, we also repaid at maturity our $500 million 1.900% Senior Notes due June 2025 and accrued and unpaid interest with respect to such notes. Financial Covenant As of June 30, 2026, we were in compliance with the financial covenant required by our credit agreements described above. Covenant RequirementActual as of June 30, 2026as of June 30, 2026 Maximum permitted leverage ratio(1) 4.00 times2.02 times (1) Ratio of total debt to deemed consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), as defined by each of the 2026 Revolving Credit Agreement, the 364-Day Revolving Credit Agreement and the Term Loan Credit Agreement. Under each of the 2026 Revolving Credit Agreement, 364-Day Revolving Credit Agreement and Term Loan Credit Agreement, we are required to maintain a maximum permitted leverage ratio, as defined in the agreements, of 3.75 times. The credit 46 Table of Contents agreements provide for higher leverage ratios, at our election, for the period following a qualified acquisition, as defined in the agreements, for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. It steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the applicable credit agreement. The financial covenant is substantially similar to the covenant that was required under the 2021 Revolving Credit Agreement, which we terminated on February 26, 2026. On November 15, 2024, we announced the closing of our acquisition of Axonics, Inc. (Axonics) which we had previously designated as a qualified acquisition under the 2021 Revolving Credit Agreement, increasing the maximum permitted leverage ratio to 4.75 times at that time. We continued such designation under the new credit agreements. Consequently, as of June 30, 2026, the maximum permitted leverage ratio is 4.00 times. We believe that we have the ability to comply with the financial covenant for the next 12 months. The financial covenant requirement provides for an exclusion from the calculation of consolidated EBITDA, through maturity, of certain charges and expenses. Permitted exclusions from the calculation of consolidated EBITDA include any non-cash charges and any cash litigation payments (net of any cash litigation receipts), as defined in the credit agreements, provided that the sum of any excluded net cash litigation payments since December 31, 2025 does not exceed $1.160 billion. As of June 30, 2026, we had $1.115 billion of the total permitted exclusion remaining. Contractual Obligations and Commitments On January 15, 2026, we announced our entry into a definitive agreement to acquire 100 percent of Penumbra, a publicly traded medical technology company primarily focused on thrombectomy products for use in peripheral vascular procedures in the removal of blood clots and blockages. At the time of announcement, the purchase price was valued at $374 per share, or approximately $14.500 billion. On March 16, 2026, we and Penumbra each received a request for additional information (Second Request) from the United States Federal Trade Commission (FTC) in connection with its review of the transaction. We and Penumbra are responding to the Second Request and continue to work cooperatively with the FTC in its review. On May 6, 2026, Penumbra stockholders voted to approve the acquisition. The transaction is expected to be completed in the second half of 2026, subject to the satisfaction of other customary closing conditions, including regulatory clearances. We plan to fund the transaction consideration through a combination of cash on hand and newly issued debt in an aggregate amount equal to approximately $11.000 billion, and the remaining portion of the transaction consideration will be paid in shares of our common stock. The Penumbra business will be integrated into our Cardiovascular division. Certain of our acquisitions involve the payment of contingent consideration. Refer to Note B Acquisitions and Strategic Investments to our unaudited consolidated financial statements contained in Part I, Item 1 of this Quarterly Report for further details regarding the estimated potential amount of future contingent consideration we could be required to pay associated with our acquisitions. There have been no other material changes to our contractual obligations and commitments as of June 30, 2026. Equity On February 18, 2026, our Board of Directors approved a $4.000 billion increase to our existing authorization to repurchase up to $1.000 billion of our common stock, increasing the total repurchase authorization to $5.000 billion. On May 18, 2026, we entered into an accelerated share repurchase agreement (the ASR agreement) with JPMorgan Chase Bank, National Association (JPMorgan). On May 19, 2026, under the terms of the ASR agreement, we made an aggregate upfront payment of $2.000 billion to JPMorgan and received an initial delivery of approximately 30 million shares of our common stock, representing approximately 80 percent of the transaction value based on the closing price of our common stock on May 15, 2026. The final settlement occurred on June 12, 2026, and we received approximately 10 million additional shares of our common stock. As of June 30, 2026, we had $3.000 billion remaining available under the share repurchase authorization. We did not repurchase any shares of our common stock in the first six months of 2025. Shares of our common stock may be repurchased under the stock repurchase program from time to time through open market purchases, block trades, private transactions or accelerated or other structured share repurchase programs. The extent to which we repurchase shares of our common stock, and the timing of such purchases, will depend upon a variety of factors, including market conditions, regulatory requirements and other considerations, as determined by the Company. The stock repurchase program may be suspended or discontinued at any time. 47 Table of Contents Legal Matters For a discussion of our material legal proceedings, refer to Note H Commitments and Contingencies to our unaudited consolidated financial statements contained in Part I, Item 1 of this Quarterly Report and Note I Commitments and Contingencies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K. Recent Accounting Pronouncements Information regarding new accounting pronouncements implemented since December 31, 2025, and relevant accounting pronouncements to be implemented in the future are included in Note N New Accounting Pronouncements to our unaudited consolidated financial statements contained in Part I, Item 1 of this Quarterly Report. Additional Information Use of Non-GAAP Financial Measures To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with U.S. GAAP and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes. To calculate adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share, we exclude certain charges (credits) from GAAP net income and GAAP net income attributable to Boston Scientific common stockholders, which include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), European Union (EU) Medical Device Regulation (MDR) implementation costs, debt extinguishment net charges, deferred tax expenses (benefits), discrete tax items and other charges (credits) as appropriate. Amounts are presented after-tax using our effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB ASC Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." In addition to the explanation below, please refer to Item 7. Management s Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission for an explanation of each of these adjustments and the reasons for excluding each item. The following is an explanation of each incremental or revised adjustment type, since our most recent Annual Report on Form 10-K, that management excluded as part of these non-GAAP financial measures as well as the reason for excluding each item: Restructuring and restructuring-related net charges (credits) - These adjustments primarily represent severance and other compensation-related charges, fixed asset write-offs, contract cancellations, project management fees, facility shut down costs, costs to transfer manufacturing lines between geographically dispersed facilities and other direct costs associated with our restructuring plans. These restructuring plans each consist of distinct initiatives that are fundamentally different from our ongoing, core cost reduction initiatives in terms of, among other things, the frequency with which each action is performed and the required planning, resourcing, cost and timing. Examples of such initiatives include the movement of business activities, facility consolidations and closures and the transfer of product lines between manufacturing facilities, which, due to the highly regulated nature of our industry, requires a significant investment in time and cost to create duplicate manufacturing lines, run product validations and seek regulatory approvals. Restructuring plans take place over a defined timeframe and have a distinct project timeline that requires, and begins subsequent to, approval by our Board of Directors. In contrast to our ongoing cost reduction initiatives, restructuring plans typically result in duplicative cost and exit costs over the defined timeframe and are not considered part of our core, ongoing operations. In addition, we may incur certain charges such as severance and other compensation-related charges, fixed asset write-offs, contract cancellations, facility shutdown costs, and inventory write-downs associated with discontinuations of significant product lines. These restructuring plans and activities are incremental to the core activities that arise in the ordinary course of our business. Restructuring and restructuring-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance. 48 Table of Contents Deferred tax expenses (benefits) - These amounts represent significant non-cash tax benefits arising from internal reorganizations or intra-entity asset transfers. The deferred tax effects related to the establishment and subsequent reversal of net deferred tax assets are excluded from management's assessment of operating performance used for making operating decisions and assessing performance. IEEPA tariff refund - This amount relates to the benefit recognized in connection with the recovery of previously incurred tariffs imposed under the International Emergency Economic Powers Act (IEEPA) recognized in Cost of products sold within our accompanying unaudited consolidated statements of operations. This amount is excluded from management's assessment of operating performance used for making operating decisions and assessing performance. The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) attributable to Boston Scientific common stockholders and GAAP net income (loss) per common share - diluted, respectively. To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales reported on a GAAP basis. Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included below and under Executive Summary and Results of Operations above. Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance. We believe that presenting adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders, adjusted net income (loss) per share, operational and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results through the eyes of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance. 49 Table of Contents The following is a reconciliation of our results of operations prepared in accordance with GAAP to those adjusted results considered by management. Refer to Executive Summary and Results of Operations for a discussion of these reconciling items: (in millions, except per share data)Income Tax Expense (Benefit)Net Income (Loss)Net Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per Share Reported1,060 $155 $905 $(2)$907 $0.61 Non-GAAP adjustments:27 206 2 203 0.14 20 72 72 0.05 Restructuring and restructuring-related net charges/credits5 37 37 0.02 Litigation-related net charges/credits16 60 60 0.04 Investment portfolio net losses/gains and impairments(0)(2) (2)(0.00) EU MDR implementation costs1 6 6 0.00 (7)(77) (77)(0.05) Deferred tax expenses/benefits(70)70 70 0.05 1,423 $148 $1,275 $1 $1,275 $0.86 (in millions, except per share data)Income Tax Expense (Benefit)Net Income (Loss)Net Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per Share Reported941 $146 $795 $(2)$797 $0.53 Non-GAAP adjustments:32 193 2 191 0.13 Goodwill and other intangible asset impairment charges8 37 37 0.02 Acquisition/divestiture-related net charges/credits0 (92) (92)(0.06) Restructuring and restructuring-related net charges/credits19 142 142 0.10 0 (2) (2)(0.00) EU MDR implementation costs1 9 9 0.01 (45)45 45 0.03 Discrete tax items(0)0 0 0.00 Adjusted1,289 $162 $1,127 $0 $1,127 $0.75 50 Table of Contents (in millions, except per share data)Income Tax Expense (Benefit)Net Income (Loss)Net Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per Share Reported2,222 $(21)$2,243 $(4)$2,247 $1.51 Non-GAAP adjustments:55 410 5 406 0.27 36 103 103 0.07 Restructuring and restructuring-related net charges/credits8 69 69 0.05 Litigation-related net charges/credits16 60 60 0.04 Investment portfolio net losses/gains and impairments(33)(106) (106)(0.07) EU MDR implementation costs2 12 12 0.01 (7)(77) (77)(0.05) Deferred tax expenses/benefits250 (250) (250)(0.17) 2,771 $305 $2,465 $1 $2,464 $1.66 (in millions, except per share data)Income Tax Expense (Benefit)Net Income (Loss)Net Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per Share Reported1,746 $279 $1,467 $(4)$1,471 $0.98 Non-GAAP adjustments:62 383 4 378 0.25 Goodwill and other intangible asset impairment charges8 37 37 0.02 Acquisition/divestiture-related net charges/credits(4)61 61 0.04 Restructuring and restructuring-related net charges/credits26 184 184 0.12 2 5 5 0.00 EU MDR implementation costs3 19 19 0.01 (91)91 91 0.06 Discrete tax items(0)0 0 0.00 Adjusted2,533 $284 $2,249 $1 $2,248 $1.51 51 Table of Contents ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK We develop, manufacture and sell medical devices globally and our earnings and cash flows are exposed to market risk from changes in currency exchange rates and interest rates. We address these risks through a risk management program that includes the use of derivative financial instruments. We operate the program pursuant to documented corporate risk management policies. We do not enter derivative transactions for speculative purposes. Gains and losses on derivative financial instruments substantially offset losses and gains on underlying hedged exposures. Furthermore, we manage our exposure to counterparty risk on derivative instruments by entering into contracts with a diversified group of major financial institutions and by actively monitoring outstanding positions. Our currency risk consists primarily of foreign currency denominated firm commitments, forecasted foreign currency denominated intercompany and third-party transactions and net investments in certain subsidiaries. We use both nonderivative (primarily European manufacturing operations) and derivative instruments to manage our earnings and cash flow exposure to changes in currency exchange rates. We had currency derivative instruments outstanding in the contract amount of $14.384 billion as of June 30, 2026 and $12.726 billion as of December 31, 2025. A ten percent appreciation in the U.S. dollar s value relative to the hedged currencies would increase the derivative instruments fair value by $854 million as of June 30, 2026 compared to $804 million as of December 31, 2025. A ten percent depreciation in the U.S. dollar s value relative to the hedged currencies would decrease the derivative instruments fair value by $1.042 billion as of June 30, 2026 compared to $982 million as of December 31, 2025. Any increase or decrease in the fair value of our currency exchange rate sensitive derivative instruments would be substantially offset by a corresponding decrease or increase in the fair value of the hedged underlying asset, liability or forecasted transaction, resulting in minimal impacts on our unaudited consolidated statements of operations. Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. We had no interest rate derivative instruments outstanding as of June 30, 2026 or December 31, 2025. As of June 30, 2026, $10.859 billion in aggregate principal amount of our outstanding debt obligations was at fixed interest rates, representing approximately 87% of our total debt, on an amortized cost basis. As of June 30, 2026, our outstanding debt obligations at fixed interest rates were comprised of senior notes. Refer to Note D Hedging Activities and Fair Value Measurements to our unaudited consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q for further information regarding our derivative financial instruments. 52 Table of Contents ITEM 4.CONTROLS AND PROCEDURES Evaluation of Disclosure Controls and Procedures Our management, with the participation of our President and Chief Executive Officer (CEO) and our Executive Vice President and Chief Financial Officer (CFO), evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2026 pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Disclosure controls and procedures are designed to ensure that material information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission s rules and forms and ensure that such material information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Based on their evaluation, our CEO and CFO concluded that, as of June 30, 2026, our disclosure controls and procedures were effective. Changes in Internal Control over Financial Reporting Previously, we began a multi-year implementation of a new global enterprise resource planning (ERP) system, which will replace our existing system. The implementation has been occurring in phases and will continue over the next several years. As each phase is completed, our related internal controls may change and are updated accordingly. During the second quarter of 2026, there were no changes to our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. As future phases are implemented, we expect the changes to have a material impact on our internal controls over financial reporting and we will evaluate whether these process changes necessitate further changes in the design of and testing for effectiveness of internal controls over financial reporting. 53 Table of Contents PART II OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS Refer to Note H Commitments and Contingencies to our unaudited consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q, which is incorporated herein by reference. ITEM 1A. RISK FACTORS In addition to other information contained elsewhere in this report, you should carefully consider the factors discussed in Item 1A. Risk Factors in our most recent Annual Report on Form 10-K, which could materially affect our business, financial condition or future results. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Issuer's Purchases of Equity Securities Period of RepurchaseTotal Number of Shares PurchasedAverage Price Paid Per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsApproximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs (in millions) April 1, 2026 - April 30, 2026 $ $5,000 May 1, 2026 - May 31, 2026(1) 30,372,05850.10 30,372,0583,000 June 1, 2026 - June 30, 2026(1) 9,550,37850.10 9,550,3783,000 Total39,922,436$50.10 39,922,436$3,000 (1) On February 18, 2026, our Board of Directors approved a $4.000 billion increase to our existing share repurchase authorization, increasing the total authorization to $5.000 billion. On May 18, 2026, we entered into an accelerated share repurchase agreement (the ASR agreement) with JPMorgan Chase Bank, National Association, to repurchase $2.000 billion of our common stock. On May 19, 2026, we made an aggregate upfront payment of $2.000 billion and received an initial delivery of approximately 30 million shares. The ASR agreement was fully settled on June 12, 2026, and we received approximately 10 million additional shares. Shares delivered under the ASR agreement are reflected in the table above in the periods received, including the initial delivery in May 2026 and the final settlement in June 2026. The total number of shares repurchased was based on the volume-weighted average price of our common stock during the repurchase period, less adjustments in accordance with the terms of the agreement. ITEM 5. OTHER INFORMATION (c) No director or officer adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the quarter ended June 30, 2026. ITEM 6. EXHIBITS (* documents filed or furnished with this report; # compensatory plans or arrangements) Fourth Restated Certificate of Incorporation of Boston Scientific Corporation (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on May 5, 2026, File No. 1-110183). Employee Stock Purchase Plan, Amended and Restated Effective as of July 1, 2026 (incorporated herein by reference to Exhibit 10.2 to the Company s Current Report on Form 8-K filed on May 5, 2026, File No.1-11083). Subsidiary Issuer of Guaranteed Securities (incorporated herein by reference to Exhibit 22 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed on August 1, 2025, File No. 1-11083). Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Inline XBRL Taxonomy Extension Schema Document. Inline XBRL Taxonomy Extension Calculation Linkbase Document. Inline XBRL Taxonomy Extension Definition Linkbase Document. Inline XBRL Taxonomy Extension Label Linkbase Document. Inline XBRL Taxonomy Extension Presentation Linkbase Document. Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101). By:/s/ Jonathan Monson Name:Jonathan Monson Title:Executive Vice President and Chief Financial Officer 56